Contraception and cancer: CNGOF Contraception Guidelines

• Published in: Gynécologie, obstétrique, fertilité & sénologie obstétrique, fertilité & sénologie, 2018-12, Vol.46 (12), p.834-844
• Main Authors: Pragout, D, Laurence, V, Baffet, H, Raccah-Tebeka, B, Rousset-Jablonski, C
• Format: Article
• Language: fre
• Subjects: Breast Neoplasms - epidemiology; Breast Neoplasms - etiology; Contraception, Postcoital; Contraceptive Agents, Female - adverse effects; Contraceptives, Oral, Hormonal - adverse effects; Drug Combinations; Ethinyl Estradiol - adverse effects; Female; France; Humans; Intrauterine Devices, Copper; MEDLINE; Neoplasms - chemically induced; Neoplasms - epidemiology; Neoplasms - therapy; Norpregnenes - adverse effects; Risk Factors
• ISSN: 2468-7189
• DOI: 10.1016/j.gofs.2018.10.010

To synthesize knowledge on cancer risks related to hormonal contraception and to propose recommendations on contraception during treatment and after cancer. A systematic review of the literature about hormonal contraception and cancer was conducted on PubMed/Medline and the Cochrane Library. Overall, there is no increase in cancer (all types together) incidence or mortality among hormonal contraceptive users. Estroprogestin combined contraceptive use is associated with an increased risk of breast cancer (during use), and with a reduced risk of endometrial, ovarian, lymphatic or hematopoietic cancers that persist after discontinuation, and a decreased risk of colorectal cancer. Information on cancer risk is part of the systematic information given to patients wishing contraception. However, these data will not influence its prescription, considering the positive risk/benefit balance in women without specific cancer risk factor. Contraception is required during and after cancer treatment in every non-menopausal woman at cancer diagnosis. Specific thromboembolic, immunologic or vomiting risks due to the oncological context should be taken into account before the contraceptive choice. All hormonal contraceptives are contra-indicated after breast cancer, regardless of the delay since treatment, hormone receptor status and histological subtype. There is no data in the literature to limit hormonal or non-hormonal contraceptive use after colorectal or thyroid cancer. There was insufficient data in the literature to propose recommendations on contraceptive choice after cervical cancer, melanoma, lung cancer, tumor of the central nervous system, or after thoracic irradiation. If an emergency contraception is needed in a woman previously treated for a hormone-sensitive cancer, a non-hormonal copper intrauterine device should be preferred. Information on cancer risk is part of the patient's information but does not influence the prescription of contraception in the absence of any specific risk factor. Contraception should be proposed in every woman treated or previously treated for cancer. The whole context should be taken into account to choose a tailored contraception.